Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with midostaurin under the National Health Act 1953, section 100 for patients with AML.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing midostaurin.
Section 100 arrangements
Midostaurin
This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending:
- an approved private hospital
- a public participating hospital
- a public hospital.
This item isn’t PBS-subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.
Authority applications
Applying for induction and consolidation treatment
Applications for induction and consolidation authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for initial maintenance treatment
Applications for initial maintenance authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either in:
- real time using the Online PBS Authorities system
- writing and upload through Health Professional Online Services (HPOS)
- writing and post to PBS Complex Drugs Programs.
All written applications must include the completed:
- authority prescription form or forms
- Acute myeloid leukaemia - initial maintenance authority application form
- relevant attachments.
Applying for continuing maintenance treatment
Applications for continuing maintenance authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.